Summary of the 30th Meeting of the Food and Drug Administration Gastrointestinal Drugs Advisory Committee January 16-17, 1986

Lewis, James H.
June 1986
American Journal of Gastroenterology;Jun1986, Vol. 81 Issue 6, p495
Academic Journal
Discusses three items on the agenda of the 30th meeting of the Gastrointestinal Drugs Advisory Committee of the U.S. Food and Drug Administration Office of Drug Research and Review from January 16 to 17, 1986 in Bethesda, Maryland. Single nocturnal dose of cimetidine for duodenal ulcer y(DU); Famotidine for peptic ulcer disease; Sucralfate for prevention of DU recurrence.


Related Articles

  • H2--Receptor Antagonists in the Treatment of Peptic Ulcer. Isenberg, Jon I. // Annals of Internal Medicine;Feb76, Vol. 84 Issue 2, p212 

    Comments on the efficacy of H[sub2]-receptor antagonists in the treatment of peptic ulcer. Mechanisms of H[sub2]-receptor antagonists; Information on the structure of histamine and the H[sub2]-receptor antagonists, metamide and cimetidine; Types of H[sub2]-receptor antagonists.

  • An Etiologic Approach to Management of Duodenal and Gastric Ulcers. Rex, Douglas K. // Journal of Family Practice;Jan1994, Vol. 38 Issue 1, p60 

    With rare exception, peptic ulcers can now be classified as either Helicobacter pylori-related, induced by nonsteroidal anti-inflammatory drugs (NSAIDs), or related to Zollinger-Ellison syndrome. Helicobacter pylori-related ulcers can be treated by eradication of H pylori or by traditional...

  • Antisecretorv Effect of Three Premeal Doses of Cimetidine 400 mg versus a Single Morning Dose of Omepra/ole 20 mg: Pathophysiological Implications for Duodenal Ulcer Treatment. Savarino, Vincenzo; Mela, Giuseppe Sandro; Zentilin, Patricia; Cutela, Patricia; Mansi, Carlo; Vassallo, Ambrogio; Franceschi, Massimo; Mela, Maria Raffaella; Dallorto, Enza; Celle, Guido // American Journal of Gastroenterology;Jul1993, Vol. 88 Issue 7, p1088 

    The success of omeprazole in the healing of duodenal ulcer has been attributed to its profound and almost around-the-clock inhibition of acid, but the relevance of reducing meal-stimulated acid secretion exclusively has recently been emphasized in several clinical trials. For this reason, we...

  • Double-blind Multicenter Comparison of 1,200 mg. and 1,000 mg. Cimetidine in Hospitalized and Ambulatory Duodenal Ulcer Patients. Graham, David Y.; Schwartz, Jim T.; Sabesin, Seymour M.; Mann, James A.; Davis Jr., William D.; Font, Robert G.; Cohen, Norman N. // American Journal of Gastroenterology;Dec1981, Vol. 76 Issue 6, p500 

    A multicenter double-blind study was made to compare whether 1,000 mg. dosage of cimetidine, the dose commonly employed in the United Kingdom, was as effective as the 1,200 mg. dose recommended in the United States for the treatment of duodenal ulcer. Our second goal was to test whether...

  • The Histological Maturity of Regenerating Mucosa of Healed Duodenal Ulcer and Ulcer Recurrence after Treatment with H2-Antagonist. Shiann Pan; Chen-Hsiung Liao // American Journal of Gastroenterology;Aug1990, Vol. 85 Issue 8, p949 

    We investigated the relationship between the histological maturity of regenerating mucosa of healed duodenal ulcer and ulcer recurrence, after treatment with an H2-antagonist. Duodenal ulcer patients were given H2-antagonists (either cimetidine or famotidine) for 4 wk of therapy. Fifty-two...

  • New drugs for peptic ulcer.  // British Medical Journal;7/12/1980, Vol. 281 Issue 6233, p95 

    Focuses on the effectiveness of antiulcer drugs for treatment of patients with peptic ulcer. Benefits of bed rest, stopping smoking and taking carbenoxolone for healing gastric ulcer; Side effects of anticholinergic drugs; Characteristics of trithiozine drug.

  • Does treatment with cimetidine extended beyond initial healing of duodenal ulcer reduce the subsequent relapse rate? Bardhan, K.D.; Cole, D.S.; Hawkins, B.W.; Franks, Caroline R. // British Medical Journal (Clinical Research Edition);2/27/1982, Vol. 284 Issue 6316, p621 

    Examines the impact of extended administration of cimetidine as treatment of duodenal ulcer. Determination the relapse rate; Observation of patients with silent relapse; Absence of long-term advantage.

  • Rabeprazole: A proton pump inhibitor for the treatment of acid-related disorders. Feret, Brett; Quercia, Robert A.; Cappa, Joseph // Formulary;Apr99, Vol. 34 Issue 4, p313 

    Describes the use of rabeprazole, a proton pump inhibitor and substituted benzimidazole, for the treatment of peptic ulcer and other acid-related disorders. Chemical structure and pharmacology; Clinical trials for duodenal ulcers, gastric ulcers, gastroesophageal reflux disease and H pylori...

  • Absence of toxicity in cimetidine overdosage. Illingworth, R.N.; Jarvie, D.R. // British Medical Journal;2/17/1979, Vol. 1 Issue 6161, p453 

    Discusses the absence of toxicity in cimetidine overdosage. Treatment of peptic ulceration; Occurrence of bradycardia after treatment with cimetidine; Side effect of therapeutic doses of cimetidine.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics